Florbetapir (Amyvid) PET scans may help clarify Alzheimer’s diagnoses

http://www.alz.org/news_and_events_approval-of-florbetapir.asp?WT.mc_id=enews2012_04_11

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a subsidiary of Lilly, announced U.S. Food and Drug Administration approval of florbetapir (Amyvid), its radioactive dye for use with positron emission tomography (PET) for visualization of amyloid plaque buildup in the brain. If a scan shows that a person with memory impairment has amyloid buildup in their brain, this increases the likelihood that the memory impairment is caused by Alzheimer’s disease. Additional research is needed to clarify the role of florbetapir-PET imaging in Alzheimer’s.
Read the Association’s statement >>
Read the article >>